編者按：

作為全球醫藥健康產業的積極貢獻者，藥明康德致力于通過一體化CRDMO模式，助力全球醫藥創新，為客戶、為行業、為患者創造價值。

今天，我們將目光投向歐洲。在這里，悠久的歷史與蓬勃的創新活力交融，大型藥企、新銳生物技術公司、權威研究機構云集，學術與產業的網絡緊密交織，不斷推動科學成果的轉化，為患者帶去希望。

但行業媒體BioXconomy指出，盡管研究創新在持續大量地涌現，歐洲生物技術領域目前依然面臨資金和轉化挑戰。要讓實驗室里的突破真正成為最終問世的產品，對小型biotech公司來說尤為不易。

• 如何連接歐洲的區域創新中心，進一步合作釋放創新的活力？

• 如何加速科學成果轉化，幫助新興biotech公司攻克資金挑戰？

• CRDMO將如何助力共建可持續發展的醫藥創新生態圈？

最近，藥明康德聯席首席執行官楊青博士與BioXconomy對話，分享了自己對于行業發展和區域創新的洞見。

以下為對話實錄，圖片為編者添加。

BioXconomy: 您認為歐洲應當如何更好地發揮其科學創新優勢？

楊青博士：歐洲擁有杰出的科研人才，但要將突破性發現轉化為真正的商業化新藥，歷來是充滿挑戰的。雖然美國的資金更豐厚，但歐洲可以通過簡化從基礎研究到產品問世的轉化流程，提升創新效率。藥明康德的一體化CRDMO模式就能為這一過程提供切實的價值。

在美國，生物技術行業成功的一個關鍵因素就是創新者與合同研究組織（CRO）、合同開發與生產組織（CDMO）和合同生產組織（CMO）之間的廣泛合作。通過體系化、模塊化地合作，從早期引入一體化CRDMO服務，協同加速研發轉化，到更強大的泛歐合作，相信歐洲也能涌現出更多更具可持續性和增長潛力的biotech公司。

BioXconomy: CRDMO平臺具體有哪些優勢？

楊青博士：CRDMO能夠提供覆蓋藥物開發完整價值鏈的能力技術和規模設施，同時也承擔著關鍵的教育職能：它能夠支持學術機構孵化的公司和新興企業跨越產業化的鴻溝，從容應對監管框架、行業質量標準和規模化流程。例如，一家大學孵化的公司要開發新型多肽療法，可能會缺乏制劑工藝或GMP（藥品生產質量管理規范）生產經驗。通過與藥明康德這樣的CRDMO合作，既能獲得高效的執行落地能力，又能吸收關鍵的產業化經驗。

▲藥明康德一體化CRDMO平臺，端到端賦能新藥從早期發現、開發到生產的全流程

BioXconomy: 您能否具體談談藥明康德在歐洲的能力和戰略？

楊青博士：歐洲是藥明康德重要的戰略發展區域。藥明康德已在德國慕尼黑和瑞士庫威設有運營基地，其中，慕尼黑基地專注于早期藥物發現服務，提供X射線晶體結構解析、蛋白質科學、生物物理分析等定制化服務；庫威基地則深耕制劑生產包裝，致力于為后期臨床和商業規模生產提供靈活高效的服務。

▲藥明康德在歐洲持續建能力、擴規模，目前已在德國慕尼黑（上圖）和瑞士庫威（下圖）設有兩個運營基地

我們對歐洲的投入遠不止于基地運營，還深度融入當地生態圈，包括支持可持續發展。例如，我們的瑞士基地采用地熱能、太陽能與雨水回收系統等環保節能設施；我們在歐洲的發展注重培養當地管理團隊與技術人員，為社區做出積極的貢獻。

此外，我們與歐洲當地學術機構、風投機構和新興生物技術公司積極合作，舉辦生態圈活動，建立戰略合作伙伴關系。這種全方位的參與，使藥明康德不僅僅是服務的提供商，更是歐洲生物醫藥創新發展的重要賦能者。

BioXconomy: 您剛剛提到了可持續發展。對您來說，一個可持續發展的生物醫藥創新生態圈意味著什么？

楊青博士：可持續的生物醫藥創新生態圈是一套強大的體系，在這里，創新研究能夠從早期發現無縫推進到最終實現，biotech公司不再需要大量的早期投資，而能持續通過外部風投資金，構建多元、長期的管線，實現平穩發展。

各科學創新中心之間的合作深化也同樣重要。不同地區各有所長，比如德國的慕尼黑擅長早期孵化，柏林更專注臨床研究，海德堡則深耕基礎科學——通過不同模塊的合作，我們將連接這些生物技術中心，打造更有力的創新格局。這些合作還應在全球范圍內拓展，比如連接美國、英國的產業集群，對各地最佳實踐兼容并包，并持續開拓新的創新機遇。

美國馬薩諸塞州的生物技術生態就是創新合作的典范，它成功整合了基礎研究、資金、戰略投資者、豐富的產業經驗與能力規模，為歐洲的潛在成功路徑提供了藍圖。

BioXconomy: 資金層面的挑戰仍然不容忽視。風投公司如何改變其與（新藥）開發合作伙伴的關系？這會帶來哪些影響？

楊青博士：隨著生物技術公司現在常常傾向后期退出，風投公司對產品商業化的機會和加速開發能力的期望也越來越高。投資者普遍尋求清晰、合規且高效的上市途徑，這些因素將直接影響企業估值和退出潛力。

對于資金、資源有限的小型和新興生物科技公司而言，與CRDMO合作的價值就尤其顯著。

CRDMO始終圍繞“質量、速度、成本”三大價值鏈，形成了強大的“飛輪”效應，能夠為創新企業極致賦能，幫助客戶將管線推進至關鍵的價值創造里程碑，以此提升估值，吸引投資，助力新藥好藥加速問世。

▲藥明康德CRDMO平臺圍繞“質量、速度、成本”三大價值鏈，形成了強大的“飛輪”效應，能夠為不同規模的創新企業極致賦能

Scaling success: How WuXi AppTec aims to catalyze Europe's biotech transformation

In this exclusive interview, co-CEO of WuXi AppTec Steve Yang shares insights on strengthening Europe's biotech ecosystem through strategic CRDMO partnerships.

Europe's biotech space is hampered by a notable disparity: an abundance of research innovation existing in parallel with capital and commercialization challenges. While the region excels in fundamental research and early discovery, European biotechs often struggle with the capital-intensive journey from laboratory breakthrough to market-ready product.

Yang spoke to BioXconomy about how Europe can better capitalize on its scientific strengths through integrated development partnerships and ecosystem collaboration. As WuXi AppTec expands its European footprint with specialized facilities in Germany and Switzerland, Yang provided insights on connecting regional innovation hubs, navigating funding challenges, and building sustainable growth models that could potentially transform Europe's scientific know-how into commercial leadership.

BioXconomy (BX): How do you think Europe could better capitalize on its scientific strengths?

Steve Yang (SY):Europe has exceptional scientific talent, but historically, there's been a gap in translating groundbreaking discoveries into commercial development. While funding has traditionally been stronger in the US, Europe can significantly improve its innovation output by streamlining the translation from basic research to market-ready products. This is precisely where WuXi AppTec's integrated contract research development and manufacturing organization (CRDMO) model creates tangible value.

A key reason for the success of the US biotech sector is the adoption of CRO, CDMO, and CMO services. By embracing structured scalability, early-stage engagement with integrated CRDMOs, effective tech transfer, and stronger pan-European collaborations, Europe can develop more sustainable, growth-oriented biotech companies rather than short-term projects.

BX: What advantages does a CRDMO provide?

SY:A CRDMO not only provides infrastructure and technical capabilities across the entire drug development cycle but also plays a key educational role: it supports academic spin-offs and early-stage companies in navigating regulatory frameworks, industrial quality standards, and scale-up processes. For example, a university spin-off developing a novel peptide therapy may lack experience in formulation or good manufacturing practice (GMP) production; by partnering with a CRDMO like WuXi AppTec, it gains both executional capacity and critical industry knowledge.

BX: Could you speak specifically about WuXi AppTec's capabilities and strategy in Europe?

SY:Europe represents our next major strategic growth frontier. WuXi AppTec already maintains operational sites in Munich, Germany, and Couvet, Switzerland […] Munich focuses on early-stage drug discovery and provides customized services in drug discovery, X-ray crystallography, protein supply, and biophysical analysis. Couvet specializes in drug product manufacturing and packaging, offering flexibility in late-stage clinical and commercial-scale production.

Yet this commitment extends beyond operational presence to integration in local ecosystems, including investments in sustainability, such as geothermal energy, solar power, and rainwater recycling at our Swiss site. Our European expansion also prioritizes empowering local management and fostering workforce development to ensure long-term, community-driven growth.

We proactively collaborate with European academic institutions, venture capital (VC) investors, and emerging biotech companies through ecosystem-building events and strategic partnerships. This active engagement ensures WuXi AppTec remains not merely a service provider, but rather a pivotal enabler of Europe's long-term biotech innovation and growth.

BX: You mentioned sustainability. What does a sustainable biotech ecosystem mean to you?

SY:A sustainable biotech ecosystem means having a robust framework where innovative research seamlessly progresses from discovery through commercial realization. It's about enabling biotech companies to scale effectively without large upfront investments, attracting sustained venture capital interest, and building diversified, long-term pipelines.

Equally important is the need to deepen collaboration between scientific hubs. Different regions have distinct strengths, Munich excels in early-stage venturing, Berlin in clinical research, and Heidelberg in fundamental science. Connecting these hubs through structured partnerships will create a more cohesive innovation landscape. This collaboration should also extend internationally, with clusters in the US and UK, offering exposure to best practices and new market opportunities.

A proven example is the Massachusetts biotech ecosystem, renowned for effectively integrating foundational research, capital, strategic investors, industry expertise, and scalable development capacities, providing a clear blueprint for Europe's potential success.

BX: We can’t ignore the financial side of things. How are VCs changing their approach to development partners, and what implications does this have?

SY:With biotech companies now often pursuing later-stage exits, VCs have heightened expectations regarding commercial readiness and accelerated product development. Investors look for clear, compliant, and efficient routes to market, as these directly influence valuations and exit potentials.

Small and emerging biotech firms, typically capital- and resource-constrained, benefit significantly by partnering with comprehensive CRDMOs.

This "flywheel" model, driven by consistent quality, speed, and cost-efficiency, ensures continuous innovation momentum, helping clients achieve higher valuations, attract investment, and ultimately reach markets faster and more reliably.

免責聲明：本文僅作信息交流之目的，文中觀點不代表藥明康德立場，亦不代表藥明康德支持或反對文中觀點。本文也不是治療方案推薦。如需獲得治療方案指導，請前往正規醫院就診。

版權說明：歡迎個人轉發至朋友圈，謝絕媒體或機構未經授權以任何形式轉載至其他平臺。轉載授權請在「藥明康德」微信公眾號回復“轉載”，獲取轉載須知。